Trials / Completed
CompletedNCT00421031
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 540 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as its influence on sleep parameters and other health outcomes indicators.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 SR |
Timeline
- Start date
- 2003-12-01
- Completion
- 2004-04-01
- First posted
- 2007-01-11
- Last updated
- 2007-01-11
Locations
41 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00421031. Inclusion in this directory is not an endorsement.